Ocular Surface Microbiome in Dry Eye Patients
NCT02161341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82
Last updated 2018-10-31
Summary
The ocular surface is the first line of defence of the eye, it is therefore where external threats are sensed, and potential insults neutralised. Over the course of evolution, various microbes, especially bacteriae, have come to colonise the ocular surface as commensals. The commensals have a role to maintain the homeostasis of the ocular surface. 1 The innate immunity of the ocular surface is very active, and consists of active mechanisms to suppress inflammation 2. For example, there exist macrophages, dendritic cells, suppressor cells, regulatory cells, B cells, IgA, lysozyme, anti-microbial peptides and barriers against external agents. The normal commensals of the ocular surface maintain a basal level of activation of innate defence by stimulating the pattern recognition receptors on ocular surface epithelial cells. This normal composition of microbes is important since inflammation and infection will result if there is introduction of a pathogenic strain that overcomes the flora, or if a dominant strain secretes excessively immunogenic products, such as the exotoxin A of Staphylococcus which triggers marginal keratitis, a form of type IV hypersensitivity. The flora load of microbiome could also influence tear function as a higher flora load was found to be associated with increased mucin degradation 3 and reduced globet cell densitiy 4. Previous studies \[I'm not sure which studies these are\] at SERI/SNEC also point to the importance of microbes. For example, in dry eye patients, there is increased lysophospholipids in the tear, and this may contribute to inflammatory mediators such as arachidonic acid and other metabolites. The lysophospholipids are formed by phospholipase A2 reactions, and the latter may be microbial in origin. Since dry eye is a known inflammatory disease of the ocular surface, this is one way that microbes can contribute to the pathology.
Conditions
- Dry Eye
Sponsors & Collaborators
-
Singapore National Eye Centre
lead OTHER_GOV
Eligibility
- Min Age
- 21 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-06-30
- Primary Completion
- 2018-10-31
- Completion
- 2018-10-31
Countries
- Singapore
Study Locations
More Related Trials
-
Ocular Surface Immune Response in Dry Eye Disease
NCT02042820 ·Status: COMPLETED
-
Influencing Factors on Dry Eye Syndrome and Ocular Surface Disease
NCT03364322 ·Status: COMPLETED
-
Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation
NCT06936462 ·Status: COMPLETED ·Phase: NA
-
Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
NCT02712762 ·Status: COMPLETED
-
Dry Eye Symptoms and Quality of Life
NCT01988597 ·Status: COMPLETED
-
The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients
NCT01250171 ·Status: COMPLETED ·Phase: PHASE2
-
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders
NCT03731624 ·Status: UNKNOWN
-
Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome
NCT02715323 ·Status: COMPLETED
-
Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
NCT01459588 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
NCT04139122 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
NCT01181713 ·Status: COMPLETED
-
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
NCT06411132 ·Status: TERMINATED
-
Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
NCT04198740 ·Status: RECRUITING
-
Dry Eye Evaluation System Based on Bioinformatics
NCT04109170 ·Status: UNKNOWN
-
The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects
NCT05287425 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction
NCT01600625 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
NCT05119920 ·Status: COMPLETED ·Phase: PHASE2
-
Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs
NCT02819232 ·Status: COMPLETED ·Phase: NA
-
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
NCT05322148 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye
NCT02160327 ·Status: UNKNOWN
-
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
NCT02435914 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation on Medical Management of Dry Eye Patients
NCT01942226 ·Status: COMPLETED
-
Comparing the Quality of Topical Autologous Serum in Different Etiologies of Dry Eye Syndrome
NCT02774707 ·Status: UNKNOWN
-
Mucin Levels in Dry Eye and Normal Populations
NCT05911555 ·Status: COMPLETED
-
Are Corneal Epithelial Defects Related to Changes in Ocular Bacterial Flora in Patients With ANLDO
NCT02234700 ·Status: UNKNOWN